Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1725)	5/20/2001 2:55:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

And not included on the table, but mentioned on the article are: ONXX which has completed two Phase II trials of its Onyx-015 on late stage head & neck cancers with somewhat impressive results.(ONXX founder Frank McCormick's photo as well as BIOM's Longenecker were included on the article) Also not include on the table is TLRK, which has commenced human testing of three cancer drug candidates: (T67),T607), and (T64). T67 acts on the same protein targeted by Taxol and vincristine. It reportedly has the advantage that it retains its activity against tumor cells that are multiple drug resistant and is able to enter the brain. Bernard